Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic ...

President Donald Trump may hope his tariffs bring manufacturing and jobs to the U.S., but the reality is not so simple, ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

The Bondsman premieres 3 April on Amazon Prime internationally Netflix contributes to the apparently endless stream of soapy ...

In Character Limit, the New York Times reporters Kate Conger and Ryan Mac suggest that at some point ‘Musk’s Twitter habit became an addiction.’ It was especially pronounced during the pandemic, when ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...